Does advance care planning work? The evidence is more mixed than the pitch

Advance care planning — talking through and recording what medical care a person would want near the end of life, and who should speak for them — is widely promoted as a way to ensure people get the care they want. The evidence supports some of that promise and undercuts part of it. Planning ahead reliably makes wishes more likely to be known and followed and eases the distress of surviving relatives [s1]. But across the wider trial literature, it has not consistently delivered its headline goal: care that actually matches a patient's stated priorities [s2]. The gap between those two findings is where the honest discussion sits.

This is a summary of research, not guidance on personal decisions, which are individual and best made with clinicians and family.

The trial that shows it working

The strongest single demonstration is an Australian randomised trial of 309 competent medical inpatients aged 80 or older, followed for six months or until death [s1]. Of the 154 randomised to it, 125 (81%) actually received facilitated advance care planning — structured help to reflect on goals and values, consider future treatment preferences, appoint a surrogate and document wishes [s1]. Uptake among those was high: 84% expressed wishes or appointed a surrogate, or both [s1].

Among the 56 patients who died within six months, the difference was large. End-of-life wishes were known and followed in 86% of the intervention group (25 of 29) against 30% of controls (8 of 27; P<0.001) [s1]. The benefit extended to families: relatives of patients who died reported significantly less stress, anxiety and depression than the families of control patients [s1]. For the outcome of wishes being honoured, and for the wellbeing of the bereaved, advance care planning clearly did something.

The evidence that complicates it

Zooming out from one trial to the field changes the picture. A scoping review examined 69 randomised trials of advance care planning [s2]. On earlier steps in the chain, results were strongly positive: 72% of "process" outcomes such as readiness, and 86% of "action" outcomes such as communication, favoured the intervention [s2]. Satisfaction with communication was positive in 100% of comparisons, and patient-surrogate-clinician congruence in 88% [s2]. Advance care planning is good at getting people to think, talk and record.

But two of the outcomes it is ultimately sold on held up less well. Goal-concordant care — whether the care delivered actually matched what the patient said they wanted — was not among the reliably positive results [s2]. Nor was patient quality of life, and healthcare-utilisation effects were mixed [s2]. What the review did find robustly was reduced distress in surrogates and clinicians [s2]. So the process works and the people around the patient benefit; the proof that the patient's own care ends up aligned with their goals is weaker than the enthusiasm implies.

How to read this

The reconciliation is that advance care planning delivers some real goods — wishes documented and more often honoured in focused trials, families left less traumatised — while falling short of the grander claim that it systematically produces goal-concordant care at the end of life. Part of the gap is structural: a preference recorded months or years earlier may not fit the actual clinical situation that arises, and the surrogate or clinician may still not act on it. That the review found congruence between patients, surrogates and clinicians improving while goal-concordant care did not is the tension in miniature — agreement in the abstract does not guarantee aligned care at the bedside [s2]. That shortfall has driven a genuine debate in palliative medicine about whether the emphasis should shift from completing documents in advance toward better in-the-moment communication when decisions are actually being made. Both the trial and the review point the same way for individuals: the conversation and the appointed surrogate matter, perhaps more than any paperwork.

The subject sits alongside the broader strain on families and systems caring for older people — the health toll on family caregivers, what helps in dementia caregiving, and how societies fund late-life care, as in Japan's long-term care insurance.

What to watch

The field is actively rethinking its central metric. Expect more trials measuring goal-concordant care directly, and more attention to serious-illness communication at the bedside rather than advance documentation alone. The most defensible current reading is that planning helps at the margins that matter to families, without guaranteeing the outcome it is most often promised on.